Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-11-30
2003-02-11
Kunz, Gary (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C514S012200
Reexamination Certificate
active
06518235
ABSTRACT:
BACKGROUND OF THE INVENTION
(1) Field of the Invention
The present invention relates to a drug for improvement of brain function which includes leptin of the mammals as an effective component, and particularly to such a drug for improvement of brain function which is effective to prevent and treat dementia such as Alzheimer's disease and cerebral apoplexy, etc., and to cure sequelae of cerebral apoplexy.
(2) Prior Art
The advancing aging society is becoming serious as a social problem in recent years. With the advancement of the aging society, the number of patients of dementia such as Alzheimer's disease is showing a tendency to increase, and a development of a remedy for these dementia is in an urgent need. In the meantime, existence of leptin has been known from a long time ago. It has been made clear by various studies that leptin is found at an exceptionally high density only in fat tissue and that it acts to regulate food intake and to increase energy consumption, therefore, it is under development for use as an anti-obesity drug and antidiabetics.
SUMMARY OF THE INVENTION
The inventors of this invention have found, as a result of further earnest study, that leptin of mammals has an action to improve brain function which is effective to prevent and to treat dementia such as Alzheimer's disease and cerebral apoplexy, etc., and to cure sequelae of apoplexy, in addition to the known actions to regulate food intake and to increase energy consumption.
The drug for improvement of brain function of this invention contains leptin of the mammals as an effective component. The above-mentioned leptins of the mammals are highly preserved by 84% in mouse-human and by 96% in mouse-rat in the homology of amino-acid level, and are known to be the protein with high homology, and are recognized to show the same physiological actions even when administered to the different kinds of animals. Therefore, as the leptin of mammals of this invention, leptin of any kinds of mammals is applicable, in which the amino acid sequence of the leptin of the animals is substantially homologous with human leptin and the physiological action of the leptin is recognized to be the same with that of human leptin. For example, mouse leptin indicated by sequence ID number 2 or rat leptin indicated by sequence ID number 3 is also applicable as well as the human leptin indicated by sequence ID number 1.
The leptin of this invention includes analogue peptide of the above-mentioned leptin, as well as the polypeptide which exists in vivo as indicated by the above-mentioned sequence ID numbers from 1 to 3 known as mature leptin in vivo. In other words, the essence of this invention is that the leptin of the mammals being a product of obese gene has, for the first time, been found to be useful as a drug for improvement of brain function. Further, the analogue peptide of leptin, which is substantially homologous with mature leptin existing in vivo and shows physiological actions similar to the mature leptin in vivo, is also included in this invention.
The human leptin indicated by the above-mentioned sequence ID number 1 is expressed as precursor polypeptide consisting of 167 amino acid residue in a cell as a product of obese gene, after which signal peptide consisting of 21 amino acid residue of the amino terminus is cut off, and is secreted in vivo as mature protein consisting of 146 amino acid residue.
The above-mentioned analogue peptide of leptin means the polypeptide in which one or plural amino acid residue/residues is/are added to, is/are removed from, or is/are replaced with the above-mentioned mature leptin in vivo. To be more specific, leptins indicated by sequence ID numbers from 4 to 6 in which methionine is added to the amino terminus of the above-mentioned leptins is one example.
As the drug for improvement of brain function of this invention, the above-mentioned leptin of mammals may include the pharmaceutically acceptable salts thereof, for example, salts with alkaline metals such as sodium and potassium, salts with alkaline earth metals such as calcium and magnesium, salts with metals such as alminum and acid addition salts with hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, thiocyanic acid, boric acid, formic acid, acetic acid, propionic acid, glycolic acid, citric acid, tartaric acid, succinic acid, gluconic acid, lactic acid, malonic acid, fumaric acid, anthranilic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid and the like. These salts can be produced from the above-mentioned free leptin, or can be transformed to each other by the methods known to public.
The drug for improvement of brain function of this invention may contain at least one of the above-mentioned leptin of mammals and the analogue peptide of the abovementioned leptin of mammals. They can either be used independently or together. When the protein which is prepared from a different kind of mammals is applied for medical treatment of man, there are not a few cases in which it causes allograft rejection or shock symptoms on the basis of immunity defense systems, therefore human leptin, namely, human leptin and analogue peptide thereof are preferable, analogue peptide of human leptin is more preferable, and analogue peptide of human leptin indicated by the sequence ID number 4 is particularly preferable.
Processes for obtaining the leptin of this invention are, for example, a process by purification and isolation from living bodies or from cultured cells, a peptide synthesis process such as a solid-phase or a liquid-phase peptide synthesis process, and a production process by use of genetic recombination technology, etc. Since the leptin of this invention consists of many amino acid residues, the production process by use of genetic recombination technology is industrially preferable.
As expression systems (host-vector systems) for production of leptine and analogue peptide thereof by use of genetic recombination engineering, there are expression systems of bacteria, yeast, insect cell and mammal cell, for example. And it is possible to obtain analogue peptide of leptine indicated by the above-mentioned sequence ID numbers from 4 to 6 by use of genetic recombination engineering, namely for example, by ligating cDNA, coding the above-mentioned sequence ID numbers from 4 to 6, with an optional expression vector and then transfecting the vector to a proper host cell.
As to the above-mentioned cDNA which codes the leptin of this invention, human and murine leptin cDNA is mentioned in PCT Japanese publication No.9-506264, and rat cDNA is mentioned in the literature of Ogawa etc. [J. Clin. Invest., page 1647, volume 96 (year 1995] etc.
The process for genetic technological production of recombinant leptin by use of leptin gene is also described in detail in the above-mentioned publication and others. Leptin of this invention can be obtained by producing in accordance with these known processes, and some of the recombinant leptins are also available in market.
For example, it is possible to obtain human recombinant leptin indicated by sequence ID number 4, in which methionine being amino acid corresponding to initiation codon is connected to the amino terminal of polypeptide indicated by sequence ID number 1, by using cDNA, wherein the necessary initiation codon is connected to the head of the cDNA corresponding to the mature protein indicated by sequence ID number 1.
In order to ascertain whether the polypepide obtained from the above-mentioned process has the intended amino acid sequence or not, the already known processes are applied. For example, it is possible to identify the amino acid sequence of the obtained polypeptide chain by fragmentating the polypeptide chain obtained as mentioned above by using a reagent which has substrate specificity such as cyanide bromide or enzyme like trypsin, purifying by high performance liquid chromatography to isolate homogeneous peptide, and identifying amino acid sequence of these peptide fragments by auto
Hori Nobuaki
Matsumiya Teruhiko
Oomura Yutaka
Sasaki Kazuo
Shiraishi Takemasa
Hollander Law Firm, P.L.C.
Kunz Gary
Landsman Robert S.
LandOfFree
Methods for improving brain function using leptin or analogs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for improving brain function using leptin or analogs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for improving brain function using leptin or analogs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3181378